Hepatitis C screening and linkage to care with a mobile clinic in Southern Denmark

Int J Drug Policy. 2023 Nov:121:104180. doi: 10.1016/j.drugpo.2023.104180. Epub 2023 Sep 13.

Abstract

Background: Knowing the prevalence of hepatitis C (HCV) in risk groups is essential for elimination. The aim of the study was to assess HCV prevalence among people with different risk profiles and the feasibility of linking people with HCV to care.

Methods: In Southern Denmark we tested people who were using shelters, cafés, and facilities for marginalized populations and the general population. We established a mobile clinic for HCV testing offering point-of-care HCV-antibody (HCV-Ab), point-of-care HCV RNA testing, and dried blood spot (DBS) testing. People with HCV infection were linked to care.

Results: Among 802 tested persons, we found an HCV-Ab /HCV RNA prevalence of 13% (n = 101) /3% (n = 24). We found a prevalence of 20% (n = 97)/5% (n = 24) among 475 persons tested at locations attended by people who inject drugs but 0%/0% when testing the general population. Of 24 people who were HCV RNA positive, 83% (n = 20) initiated treatment, 13% (n = 3) spontaneously cleared their infection, and one was lost to follow-up.

Conclusion: General population testing has limited utility while focus on settings attended by people with increased HCV risk is more feasible. Linkage of people with a current HCV infection to care is feasible.

Keywords: Hepatitis C; People who use drugs; Point-of-care testing; Screening.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Denmark / epidemiology
  • Hepacivirus / genetics
  • Hepatitis C Antibodies
  • Hepatitis C* / diagnosis
  • Hepatitis C* / drug therapy
  • Hepatitis C* / epidemiology
  • Humans
  • Mobile Health Units
  • RNA, Viral
  • Substance Abuse, Intravenous* / drug therapy
  • Substance Abuse, Intravenous* / epidemiology

Substances

  • RNA, Viral
  • Hepatitis C Antibodies
  • Antiviral Agents